Abstract:Type 2 diabetes (T2D), one of the most common diseases in the western world, is characterized by insulin resistance and impaired beta-cell function but currently it is difficult to determine the precise pathophysiology in individual T2D patients. Non-targeted metabolomics technologies have the potential for providing novel biomarkers of disease and drug efficacy, and are increasingly being incorporated into biomarker exploration studies. Contextualization of metabolomics results is enhanced by integration of study data from other platforms, such as transcriptomics, thus linking known metabolites and genes to relevant biochemical pathways. In the current study, urinary NMR-based metabolomic and liver, adipose, and muscle transcriptomic results from the db/db diabetic mouse model are described. To assist with cross-platform integration, integrative pathway analysis was used. Sixty-six metabolites were identified in urine that discriminate between the diabetic db/db and control db/+ mice. The combined analysis of metabolite and gene expression changes revealed 24 distinct pathways that were altered in the diabetic model. Several of these pathways are related to expected diabetes-related changes including changes in lipid metabolism, gluconeogenesis, mitochondrial dysfunction and oxidative stress, as well as protein and amino acid metabolism. Novel findings were also observed, particularly related to the metabolism of branched chain amino acids (BCAAs), nicotinamide metabolites, and pantothenic acid. In particular, the observed decrease in urinary BCAA catabolites provides direct corroboration of previous reports that have inferred that elevated BCAAs in diabetic patients are caused, in part, by reduced catabolism. In summary, the integration of metabolomics and transcriptomics data via integrative pathway mapping has facilitated the identification and contextualization of biomarkers that, presuming further analytical and biological validation, may be useful in future T2D clinical studies by identifying patient populations that share common disease pathophysiology and therefore may identify those patients that may respond better to a particular class of anti-diabetic drugs.

Inter-organ crosstalk during development and progression of type 2 diabetes mellitus

The roles of cell-cell and organ-organ crosstalk in the type 2 diabetes mellitus associated inflammatory microenvironment

Multi-Organ Crosstalk with Endocrine Pancreas: A Focus on How Gut Microbiota Shapes Pancreatic Beta-Cells

Β-Cell Dynamics in Type 2 Diabetes and in Dietary and Exercise Interventions

Molecular Mechanism of Islet Β-Cell Functional Alternations During Type 2 Diabetes.

The Gut Microbial Endocrine Organ in Type 2 Diabetes

Mitochondrial Dysfunction, Oxidative Stress, and Inter-Organ Miscommunications in T2D Progression

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

The role of exosome derived miRNAs in inter-cell crosstalk among insulin-related organs in type 2 diabetes mellitus

Intra- and inter-individual metabolic profiling highlights carnitine and lysophosphatidylcholine pathways as key molecular defects in type 2 diabetes

Research advances in understanding crosstalk between organs and pancreatic β‐cell dysfunction

Pathophysiology of Type 2 Diabetes Mellitus

Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes

The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System

The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives

Exosomal miRNAs and isomiRs: potential biomarkers for type 2 diabetes mellitus

Role of the Gut Microbiome in Beta Cell and Adipose Tissue Crosstalk: A Review

Abstract 690: Circulating Proteomics And Endothelial Cell Phenotype In Patients With Type 2 Diabetes Mellitus (T2DM)

Cross Talk between β Cells and Immune Cells: What We Know, What We Think We Know, and What We Should Learn

Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy

β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies